Summary
Abbott Laboratories reported strong financial results for the third quarter and the first nine months of 2019, demonstrating robust revenue growth and improved profitability. Net sales increased by 5.5% to $8.1 billion for the quarter and 3.4% to $23.6 billion year-to-date. This growth was driven by all reportable segments, with particular strength in Diagnostics and Cardiovascular & Neuromodulation products, excluding the unfavorable impact of foreign exchange rates. The company also saw significant growth in its Diabetes Care business, largely attributed to its FreeStyle Libre continuous glucose monitoring system. Profitability showed marked improvement, with operating earnings up significantly year-over-year, driven by higher sales and improved gross profit margins. Research and development investments increased, reflecting a commitment to innovation, particularly in the Cardiovascular and Neuromodulation segments, including expenses related to acquisitions. The company also highlighted progress in integrating recent acquisitions and streamlining operations. Shareholder returns were supported by a dividend increase and new share repurchase authorizations, reinforcing confidence in future performance.
Financial Highlights
50 data points| Revenue | $8.08B |
| Cost of Revenue | $3.36B |
| Gross Profit | $4.23B |
| R&D Expenses | $596.00M |
| SG&A Expenses | $2.44B |
| Operating Expenses | $6.88B |
| Operating Income | $1.20B |
| Interest Expense | $167.00M |
| Net Income | $960.00M |
| EPS (Basic) | $0.54 |
| EPS (Diluted) | $0.53 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.78B |
Key Highlights
- 1Net sales increased by 5.5% to $8.1 billion in Q3 2019 and 7.4% excluding foreign exchange impact, driven by strong performance across all reportable segments.
- 2Year-to-date net sales grew 3.4% to $23.6 billion (7.2% excluding foreign exchange), with notable contributions from Diagnostics and Cardiovascular & Neuromodulation products.
- 3Diabetes Care business, particularly the FreeStyle Libre system, showed significant growth, with year-to-date sales up 30.6% (36.5% excluding foreign exchange).
- 4Gross profit margin improved to 52.4% in Q3 2019 (from 51.5% in Q3 2018) and 52.3% year-to-date (from 50.9% in the prior year), indicating enhanced operational efficiency.
- 5Operating earnings saw substantial improvement, up significantly year-over-year for both the quarter and year-to-date, reflecting strong sales growth and margin expansion.
- 6The company declared a quarterly dividend of $0.32 per share, an increase of approximately 14% year-over-year, and authorized a new $3 billion share repurchase program.
- 7Abbott adopted the new lease accounting standard (ASU 2016-02) as of January 1, 2019, which resulted in the recognition of approximately $850 million in new right-of-use assets and operating lease liabilities.